Managed access to alpelisib for severe conditions
Treatments studied
Part of Cancer, Skin clinical trials.
This program provides access to an experimental medicine called alpelisib (also known as BYL719) for people with serious conditions who have no other treatment options and cannot participate in clinical trials. If a licensed doctor requests it, and you meet the criteria, you may be able to receive this medicine through a managed access program.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a serious or life-threatening disease, and no other standard treatments are available that work for you.
- You cannot join or continue in a clinical trial for your condition.
- Your doctor believes the possible benefit of this medicine outweighs the risks for you.
- Your doctor has requested this medicine through a special access program.
- The use of this medicine is allowed in your country's laws and regulations.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study lets people who are already taking alpelisib in another Novartis trial keep getting it after that trial ends. It checks long-term safety and continued benefit.
This trial is testing a drug called alpelisib for people with PROS (a rare condition that causes parts of the body to grow too much). The drug targets a specific gene change (PIK3CA mutation) that is often the cause. If you have this condition and it's causing serious symptoms, this study might help shrink or slow the overgrowth, improving your quality of life.
This program provides ribociclib (a targeted cancer therapy) to patients with serious or life-threatening diseases who have no other satisfactory treatment options and cannot join a clinical trial. The goal is to offer potential benefit when standard treatments have been exhausted.
This trial tests a combination of two drugs, alpelisib and pembrolizumab, for people with advanced triple-negative breast cancer or melanoma that has spread. The goal is to see if the combination can help shrink tumors, including those that have spread to the brain.
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
This trial tests alpelisib (a targeted medicine) for people who have lymphatic malformations (LyM) that cause symptoms and have a PIK3CA mutation. It may help shrink or control these lesions when other procedures are delayed until after the first 24 weeks.
Hear when a new PIK3CA-Related Overgrowth Spectrum (PROS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.